The latest price target for Prime Medicine (NASDAQ:PRME) was reported by Chardan Capital on November 13, 2024. The analyst firm set a price target for $15.00 expecting PRME to rise to within 12 months (a possible 360.12% upside). 17 analyst firms have reported ratings in the last year.

The latest analyst rating for Prime Medicine (NASDAQ:PRME) was provided by Chardan Capital, and Prime Medicine maintained their buy rating.

The last upgrade for Prime Medicine Inc happened on May 16, 2024 when Citigroup raised their price target to $10. Citigroup previously had a neutral for Prime Medicine Inc.

There is no last downgrade for Prime Medicine.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Prime Medicine, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Prime Medicine was filed on November 13, 2024 so you should expect the next rating to be made available sometime around November 13, 2025.

While ratings are subjective and will change, the latest Prime Medicine (PRME) rating was a maintained with a price target of $17.00 to $15.00. The current price Prime Medicine (PRME) is trading at is $3.26, which is out of the analyst’s predicted range.